Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.09.2017 | Original Article

Charlson Comorbidity Index, inappropriate medication use and cognitive impairment

Bermuda Triangle

verfasst von: Kamile Silay, MD, Ahmet Yalcin, Sema Akinci, Fatma Gul Gursoy, Didem Sener Dede

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2017

Einloggen, um Zugang zu erhalten

Summary

Background

The aim is to evaluate the association between the Charlson Comorbidity Index (CCI), polypharmacy, inappropriate medication use and cognitive impairment in long-term care facility patients.

Methods

A cross-sectional study including 105 long-term care facility residents was performed. The Charlson Comorbidity Index (CCI) was used. Inappropriate drug use (IDU) was defined according to the STOPP (Screening Tool of Older People’s Prescriptions) criteria. Univariate analysis to identify variables associated with patient outcome related with cognitive impairment was investigated with χ2, Pearson correlation, Fisher exact, and Mann–Whitney U test where appropriate. For the multivariate analysis, the possible factors identified with univariate analysis were further entered into logistic regression analysis.

Results

A significant difference was found between gender, CCI and cognitive impairment (p = 0.038, p = 0.01). While every one point increment in the CCI increases the risk of cognitive impairment 3.1 fold (95% CI = 1.8–5.4, p < 0.001), hypertension increases the risk 12 fold (95% CI = 2.5–67.8, p = 0.002). While the correlation between Mini-Mental Status Examination (MMSE) score and polypharmacy is significant (p = 0.015), the correlation between MMSE and IDU was insignificant (p = 0.739). The association of urogenital system drugs and dementia was significant (p = 0.044).

Conclusions

Comorbidities, especially hypertension and old age, are risk factors for cognitive impairment. Polypharmacy correlates with MMSE and is considered a risk factor for cognitive impairment. Inappropriate medication use is high among long-term care facility residents. More studies on large cohorts are needed regarding optimal drug prescription and detection of specific drugs that may have an impact on cognitive performance.
Vorheriger Artikel Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women
Nächster Artikel HPV prevalence in vulvar cancer in Austria
Literatur
1.
Murphy SL, Xu J, Kochanek KD. Division of Vital Statistics. Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61(4):1–117.PubMed
2.
Folstein M, Folstein S, McHugh P. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psych Res. 1975;12:189–98.CrossRef
3.
Schubert CC, Boustani M, Callahan CM, et al. Comorbidity profile of dementia patients in primary care: are they sicker? J Am Geriatr Soc. 2006;54:104–9.CrossRefPubMed
4.
Sanderson M, Wang J, Davis DR, et al. Co-morbidity associated with dementia. Am J Alzheimers Dis Other Demen. 2002;17:73–8.CrossRefPubMed
5.
Sarfati D, Tan L, Blakely T, et al. Comorbidity among patients with colon cancer in New Zealand. N Z Med J. 2011;124:76–88.PubMed
6.
Mnatzaganian G, Ryan P, Norman PE, et al. Accuracy of hospital morbidity data and the performance of comorbidity scores as predictors of mortality. J Clin Epidemiol. 2012;65:107–15.CrossRefPubMed
7.
Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151:1825–32.CrossRefPubMed
8.
Guaraldo L, Cano FG, Damasceno GS, et al. Inappropriate medication use among the elderly: a systematic review of administrative databases. BMC Geriatr. 2011;11:79.CrossRefPubMedPubMedCentral
9.
Gosch M, Wortz M, Nicholas JA, et al. Inappropriate prescribing as a predictor for long term mortality after hip fracture. Gerontology. 2014;60:114–22.CrossRefPubMed
10.
Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalisation and mortality a population based study of the very old. Drugs Aging. 2005;22:69–82.CrossRefPubMed
11.
Gallagher P, O’Mahony D. Screening tool of older persons’ potentially inappropriate prescriptions application to acutely ill elderly patients and comparison with beers’ criteria. Age Ageing. 2008;37:673–9.CrossRefPubMed
12.
Parsons C. Polypharmacy and inappropriate medication use in patients with dementia: an underresearched problem. Ther Adv Drug Saf. 2017;8:31–46.CrossRefPubMed
13.
Montastruc F, Gardette V, Cantet C, et al. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs. Eur J Clin Pharmacol. 2013;69:1589–97.CrossRefPubMed
14.
15.
Sköldunger A, Fastbom J, Wimo A, et al. Impact of inappropriate drug use on hospitalizations, mortality, and costs in older persons and persons with dementia: findings from the SNAC study. Drugs Aging. 2015;32:671–8.CrossRefPubMedPubMedCentral
16.
Wolf-Klein GP, Siverstone FA, Brod MS, et al. Are Alzheimer patients healthier? J Am Geriatr Soc. 1998;36:219–24.CrossRef
17.
Sanderson M, Wang J, Davis DR, et al. Co-morbidity associated with dementia. Am J Alzheimers Dis Other Demen. 2002;17:73–8.CrossRefPubMed
18.
Corrada M, Hayden KM, Bullain SS, et al. Age of onset of hypertension and risk of dementia in the oldest-old: The 90+ study. Alzheimers Dement. 2017;13:103–10.CrossRefPubMed
19.
van Kooten F, Koudstaal PJ. Epidemiology of post-stroke dementia. Haemostasis. 1998;28:124–33.PubMed
20.
Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8:1006–18.CrossRefPubMed
21.
Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005;62:1556–60.CrossRefPubMed
22.
Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63:1902–7.CrossRefPubMed
23.
Tzourio C, Laurent S, Debette S. Is hypertension associated with an accelerated aging of the brain? Hypertension. 2014;63:894–903.CrossRefPubMed
24.
Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141–5.CrossRefPubMed
25.
Rouch L, Cestac P, Hanon O, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29:113–30.CrossRefPubMed
26.
Chang-Quan H, Hui W, Chao-Min W, et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract. 2011;65:1295–305.CrossRefPubMed
27.
Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res Rev. 2009;8:61–70.CrossRefPubMed
28.
Siennicki-Lantz A, Reinprecht F, Axelsson J, et al. Cerebral perfusion in the elderly with nocturnal blood pressure fall. Eur J Neurol. 2007;14:715–20.CrossRefPubMed
29.
Elmstahl S, Rosen I. Postural hypoten-sion and EEG variables predict cognitive decline:results from a 5-year follow-up of healthy elderly women. Dement Geriatr Cogn Disord. 1997;8:180–7.CrossRefPubMed
30.
Lopponen MK, Isoaho RE, Raiha IJ, et al. Undiagnosed diseases in patients with dementia-a potential target group for intervention. Dement Geriatr Cogn Disord. 2004;18:321–9.CrossRefPubMed
31.
Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345–345.CrossRefPubMed
32.
Jyrkkä J, Enlund H, Lavikainen P, et al. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20:514–22.CrossRefPubMed
33.
Gallagher P, Barry P, O’Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32:113–21.CrossRefPubMed
34.
35.
Pasina L, Djade CD, Lucca U, et al. Association of Anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the Anticholinergic cognitive burden scale and Anticholinergic risk scale: results from the REPOSI study. Drugs Aging. 2013;30:103–12.CrossRefPubMed
Metadaten
Titel
Charlson Comorbidity Index, inappropriate medication use and cognitive impairment
Bermuda Triangle
verfasst von
Kamile Silay, MD
Ahmet Yalcin
Sema Akinci
Fatma Gul Gursoy
Didem Sener Dede
Publikationsdatum
01.09.2017
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 21-22/2017
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-017-1253-4

Weitere Artikel der Ausgabe 21-22/2017

HPV prevalence in vulvar cancer in Austria

  • Open Access
  • original article

Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus

  • short report

Molecular epidemiology of multidrug-resistant clinical isolates of Acinetobacter baumannii

  • Open Access
  • original article

Medical error and patient safety in the spotlight

  • letter to the editors

MUW researcher of the month

  • MUW researcher of the month

Gender differences and the role of parental education, school types and migration on the body mass index of 2930 Austrian school children

  • original article